Results 101 to 110 of about 41,661 (291)
Precision Medical Sciences, EarlyView.Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang +7 more
wiley +1 more source
Urological Science, 2015 It is believed that androgens and their receptors regulate normal prostate growth and mediate prostate cancer development. Androgen deprivation therapy is the most commonly used treatment for advanced prostate cancer.
Tsung-Yi Huang +10 more
doaj +1 more source
The Prostate, EarlyView.ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala +11 more
wiley +1 more source
Evolution of androgen deprivation therapy
, 2015 The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/ or blocking the androgen receptor,
Raj, G.V. +3 more
core
, 2016 Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis.
Inder, Warrick J. +10 more
core +1 more source
, 2023 Table 1: Habitual dietary intake and physical activity level at baseline and following either 20 weeks of usual care (Control) or resistance exercise training (Exercise) in prostate cancer patients on androgen deprivation therapy.
Milou Beelen (15187664) +9 more
core +1 more source
The Prostate, EarlyView.ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma +18 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar +5 more
wiley +1 more source
Sleep Research, EarlyView.Abstract A 41‐year‐old male patient presented with a 13‐year history of recurrent nocturnal penile pain associated with erections during sleep. Over the course of his illness, the patient attended outpatient clinics on 298 occasions and was hospitalized three times. The primary symptom reported was erectile pain occurring during sleep.
Liping Zhang +5 more
wiley +1 more source
Adverse effects of androgen-deprivation therapy in prostate cancer and their management
, 2015 Objective To provide an up-to-date summary of current literature on the management of adverse effects of androgen-deprivation therapy (ADT). Patients and Methods All relevant medical literature on men with prostate cancer treated with ADT from 2005 to ...
Corcoran, Niall M. +6 more
core +1 more source